The U.S. Food and Drug Administration is warning health care providers that biotin, also known as vitamin B7, can significantly interfere with certain lab tests, resulting in incorrect results that may go undetected. Used in hormone tests and tests for certain cardiac health markers such as troponin due to its ability to bond with specific proteins, biotin is also frequently found in multi-vitamins, prenatal vitamins and dietary supplements marketed for hair, nail and skin growth. FDA states that biotin in blood and other samples taken from patients who are ingesting high levels of the substance in dietary supplements can cause “significantly incorrect” test results, both falsely high and falsely low, depending on the test. The agency warns that it has seen an increase in the number of reported adverse events related to biotin interference with lab tests. FDA urges providers to talk to patients about any biotin supplements that may be taking and communicate to the lab conducting testing if a patient is taking biotin. For more, see the FDA Safety Communication. 

Related News Articles

AHA Chief Medical Officer and Senior Vice President Jay Bhatt, D.O., shares information on a new resource from AHA’s Physician Alliance to help frontline staff…
The AHA today unveiled a set of principles to he
Insights and Analysis
Glendale, Calif.-based Adventist Medical Center has built a growing community of grief support facilitators.
Insights and Analysis
In efforts to increase primary care use in the community and decrease avoidable emergency department visits, Copley Hospital in Morrisville, Vt., has spent the…
AHA’s Association for Community Health Improvement’s annual conference is a chance for health care leaders to shape population health and equity initiatives…
The last thing a patient should worry about in a health crisis is an unanticipated medical bill that unintentionally impacts their out-of-pocket costs … and…